Literature DB >> 12537976

Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?

David P Steensma1, Gordon W Dewald, Janice M Hodnefield, Ayalew Tefferi, Curtis A Hanson.   

Abstract

Cytogenetic abnormalities suggestive of a myeloid disorder are occasionally observed in the bone marrow (BM) cells of patients with morphologically and immunohistochemically unremarkable marrow aspirates and biopsies. Between 1994 and 2000, 55 such patients were seen at our institution (34 men; median age of 66 years). The indications for BM sampling included unexplained cytopenias (31 patients), staging or follow-up of a lymphoproliferative disorder or a plasma cell dyscrasia (18 patients), or another miscellaneous reason (6 patients). Specific cytogenetic abnormalities included a 20q deletion or monosomy 20 (10 patients), a chromosome 7 deletion (8 patients), +8 (5 patients), del(5q) or a 5q translocation (4 patients), and del(13q) (2 patients). Eleven patients had a complex karyotype. As of January 2002, 23 of the 55 patients were dead; median follow-up for living patients is 20 months. Of the 23 dead patients, 1 died of acute myelogenous leukemia (AML) and 6 of complications related to cytopenias. This study provides support for obtaining cytogenetic studies in patients with unexplained cytopenias if a morphologic explanation for the cytopenias is lacking. Continued follow-up of this heterogeneous cohort and further studies of similar patients will more clearly define the disease processes and prognosis for this constellation of laboratory findings.

Entities:  

Mesh:

Year:  2003        PMID: 12537976     DOI: 10.1016/s0145-2126(02)00161-3

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

Authors:  David P Steensma; Rafael Bejar; Siddhartha Jaiswal; R Coleman Lindsley; Mikkael A Sekeres; Robert P Hasserjian; Benjamin L Ebert
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

2.  Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies.

Authors:  C Cameron Yin; Jie Peng; Yu Li; Rashmi Kanagal-Shamanna; Tariq Muzzafar; Courtney DiNardo; Joseph D Khoury; Shaoying Li; L Jeffrey Medeiros; Sa A Wang; Guilin Tang
Journal:  Mod Pathol       Date:  2015-06-05       Impact factor: 7.842

3.  Comment to "Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designation" Haematologica. 2012;97(12):1845-9.

Authors:  Andreas Holbro; Martine Jotterand; Jakob R Passweg; Andreas Buser; André Tichelli; Alicia Rovó
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

4.  Mosaic chromosome 20q deletions are more frequent in the aging population.

Authors:  Mitchell J Machiela; Weiyin Zhou; Neil Caporaso; Michael Dean; Susan M Gapstur; Lynn Goldin; Nathaniel Rothman; Victoria L Stevens; Meredith Yeager; Stephen J Chanock
Journal:  Blood Adv       Date:  2017-02-13

5.  Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia.

Authors:  Machiko Fujioka; Hidehiro Itonaga; Takeharu Kato; Yasuhito Nannya; Miki Hashimoto; Sachie Kasai; Eo Toriyama; Rena Kamijo; Masataka Taguchi; Hiroaki Taniguchi; Shinya Sato; Sunao Atogami; Yoshitaka Imaizumi; Tomoko Hata; Yukiyoshi Moriuchi; Seishi Ogawa; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2019-09-12       Impact factor: 2.490

6.  Bone marrow hypoplasia, isochromosome 8q and deletion of chromosome 6q preceding B-cell lymphoma.

Authors:  Nae Yu; Yoonjung Kim; Sung-Eun Choi; Juwon Kim; Yu Ri Kim; Jong Rak Choi; Kyung-A Lee
Journal:  Blood Res       Date:  2014-09-25

7.  Myelodysplastic syndrome in elderly patients: correlation of CBC with cytogenetic and FISH analysis.

Authors:  K-E T Codispoti; L Depalma
Journal:  Int J Lab Hematol       Date:  2009-12-23       Impact factor: 2.877

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.